Loading…

Implication of Human UGT2B7, 2B15, and 2B17 in 19-Norandrosterone Metabolism

Nandrolone (19-nortestosterone) is an anabolic androgenic steroid commonly abused for doping purposes. Nandrolone is mainly metabolized in the liver into 19-norandrosterone prior to glucuronidation and excretion through urine over an extended period of time. Several UGTs (i.e., UGT2B7, UGT2B15, and...

Full description

Saved in:
Bibliographic Details
Published in:Frontiers in endocrinology (Lausanne) 2013, Vol.4, p.75-75
Main Authors: Strahm, Emmanuel, Sjöberg, Ulf, Garle, Mats, Rane, Anders, Ekström, Lena
Format: Article
Language:English
Subjects:
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c4655-8c48c2109194dbeade8668641f5f866c4896b844bc2602aab2e96eecc38b9933
cites
container_end_page 75
container_issue
container_start_page 75
container_title Frontiers in endocrinology (Lausanne)
container_volume 4
creator Strahm, Emmanuel
Sjöberg, Ulf
Garle, Mats
Rane, Anders
Ekström, Lena
description Nandrolone (19-nortestosterone) is an anabolic androgenic steroid commonly abused for doping purposes. Nandrolone is mainly metabolized in the liver into 19-norandrosterone prior to glucuronidation and excretion through urine over an extended period of time. Several UGTs (i.e., UGT2B7, UGT2B15, and UGT2B17) are thought to be the major enzymes responsible for conjugation of androgens in human. An in vitro study using recombinant enzymes expressed in insect cells showed that UGT1A4 and UGT2B7 are the two main enzymes responsible of 19-norandrosterone glucuronidation. However, the identity of the enzyme involved in nandrolone metabolism in vivo together with their relative contribution and regulation remain unknown. Inhibition assays using human liver microsomes (HLM) incubated with 19-norandrosterone and selective inhibitors confirmed that UGT2B7 and UGT2B15 are involved in 19-norandrosterone glucuronidation, since the presence of the specific UGT2B7 and UGT2B15 inhibitors gemfibrozil and valproic acid inhibited the 19-norandrosterone glucuronidation by 35 and 45%, respectively. HLM were genotyped for UGT2B15 D85Y, UGT2B7 H268Y, and the UGT2B17 deletion polymorphism. The glucuronidation activity on 19-norandrosterone was significantly higher in UGT2B15 DD than in the other UGT2B15 genotypes (p 
doi_str_mv 10.3389/fendo.2013.00075
format article
fullrecord <record><control><sourceid>proquest_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_c8beb6d971ec46a492787050a66b1e6b</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_c8beb6d971ec46a492787050a66b1e6b</doaj_id><sourcerecordid>1372697039</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4655-8c48c2109194dbeade8668641f5f866c4896b844bc2602aab2e96eecc38b9933</originalsourceid><addsrcrecordid>eNp1UstuFDEQtBARiULunNAcOWQWvx8XJBJBstKSXDZny_b0hAkz48WeBfH3eB9ZsgdOLnVXVbfahdA7gmeMafOxhbGJM4oJm2GMlXiFzoiUvKbM0Ncv8Cm6yPmpUDDHxBj9Bp1SprEgVJ2hxXxY9V1wUxfHKrbV7XpwY_Vws6RX6rKiV0RcVm5sNkhV3VgRU9_FVCop5glSHKH6BpPzse_y8BadtK7PcLF_z9Hy65fl9W29uL-ZX39e1IFLIWoduA6UYEMMbzy4BrSUWnLSirag0jXSa859oBJT5zwFIwFCYNobw9g5mu9sm-ie7Cp1g0t_bHSd3RZierQuTV3owQbtwcvGKAJltuOGKq2wwE5KT0D64lXvvPJvWK39kdu-9KMgsIJqIUXhm__yVyk2_0TPQvp87KL9tNMWwgBNgHFKrj-2OOqM3Xf7GH9ZJg3DamPwYW-Q4s815MkOXQ7Q926EuM6WMEWlUZiZQsU7aigflRO0hzEE20187DY-dhMfu41Pkbx_ud5BcNj_LyB8v9w</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1372697039</pqid></control><display><type>article</type><title>Implication of Human UGT2B7, 2B15, and 2B17 in 19-Norandrosterone Metabolism</title><source>PubMed Central</source><creator>Strahm, Emmanuel ; Sjöberg, Ulf ; Garle, Mats ; Rane, Anders ; Ekström, Lena</creator><creatorcontrib>Strahm, Emmanuel ; Sjöberg, Ulf ; Garle, Mats ; Rane, Anders ; Ekström, Lena</creatorcontrib><description>Nandrolone (19-nortestosterone) is an anabolic androgenic steroid commonly abused for doping purposes. Nandrolone is mainly metabolized in the liver into 19-norandrosterone prior to glucuronidation and excretion through urine over an extended period of time. Several UGTs (i.e., UGT2B7, UGT2B15, and UGT2B17) are thought to be the major enzymes responsible for conjugation of androgens in human. An in vitro study using recombinant enzymes expressed in insect cells showed that UGT1A4 and UGT2B7 are the two main enzymes responsible of 19-norandrosterone glucuronidation. However, the identity of the enzyme involved in nandrolone metabolism in vivo together with their relative contribution and regulation remain unknown. Inhibition assays using human liver microsomes (HLM) incubated with 19-norandrosterone and selective inhibitors confirmed that UGT2B7 and UGT2B15 are involved in 19-norandrosterone glucuronidation, since the presence of the specific UGT2B7 and UGT2B15 inhibitors gemfibrozil and valproic acid inhibited the 19-norandrosterone glucuronidation by 35 and 45%, respectively. HLM were genotyped for UGT2B15 D85Y, UGT2B7 H268Y, and the UGT2B17 deletion polymorphism. The glucuronidation activity on 19-norandrosterone was significantly higher in UGT2B15 DD than in the other UGT2B15 genotypes (p &lt; 0.05). Moreover, human liver cancer HepG2 cells were exposed to androgens to determine if the transcriptional activity of the genes of interest was affected. Only UGT2B7 mRNA expression was significantly increased (1.8-folds) after incubation with nandrolone decanoate. These results show that the UGT2B7 and UGT2B15 are involved in 19-norandrosterone glucuronidation and that the UGT2B15 polymorphism (D85Y) is the only UGT genetic variation that influences the glucuronidation activity. This could partly explain the inter-individual variation in 19-norandrosterone excretion.</description><identifier>ISSN: 1664-2392</identifier><identifier>EISSN: 1664-2392</identifier><identifier>DOI: 10.3389/fendo.2013.00075</identifier><identifier>PMID: 23805127</identifier><language>eng</language><publisher>Switzerland: Frontiers Media S.A</publisher><subject>19-norandrosterone ; anabolic androgenic steroid ; Endocrinology ; Endokrinologi och diabetes ; Klinisk medicin ; Medicin och hälsovetenskap ; Nandrolone ; UGT2B15 ; UGT2B7</subject><ispartof>Frontiers in endocrinology (Lausanne), 2013, Vol.4, p.75-75</ispartof><rights>Copyright © 2013 Strahm, Sjöberg, Garle, Rane and Ekström. 2013</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4655-8c48c2109194dbeade8668641f5f866c4896b844bc2602aab2e96eecc38b9933</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC3693077/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC3693077/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,4024,27923,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/23805127$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttp://kipublications.ki.se/Default.aspx?queryparsed=id:223805127$$DView record from Swedish Publication Index$$Hfree_for_read</backlink></links><search><creatorcontrib>Strahm, Emmanuel</creatorcontrib><creatorcontrib>Sjöberg, Ulf</creatorcontrib><creatorcontrib>Garle, Mats</creatorcontrib><creatorcontrib>Rane, Anders</creatorcontrib><creatorcontrib>Ekström, Lena</creatorcontrib><title>Implication of Human UGT2B7, 2B15, and 2B17 in 19-Norandrosterone Metabolism</title><title>Frontiers in endocrinology (Lausanne)</title><addtitle>Front Endocrinol (Lausanne)</addtitle><description>Nandrolone (19-nortestosterone) is an anabolic androgenic steroid commonly abused for doping purposes. Nandrolone is mainly metabolized in the liver into 19-norandrosterone prior to glucuronidation and excretion through urine over an extended period of time. Several UGTs (i.e., UGT2B7, UGT2B15, and UGT2B17) are thought to be the major enzymes responsible for conjugation of androgens in human. An in vitro study using recombinant enzymes expressed in insect cells showed that UGT1A4 and UGT2B7 are the two main enzymes responsible of 19-norandrosterone glucuronidation. However, the identity of the enzyme involved in nandrolone metabolism in vivo together with their relative contribution and regulation remain unknown. Inhibition assays using human liver microsomes (HLM) incubated with 19-norandrosterone and selective inhibitors confirmed that UGT2B7 and UGT2B15 are involved in 19-norandrosterone glucuronidation, since the presence of the specific UGT2B7 and UGT2B15 inhibitors gemfibrozil and valproic acid inhibited the 19-norandrosterone glucuronidation by 35 and 45%, respectively. HLM were genotyped for UGT2B15 D85Y, UGT2B7 H268Y, and the UGT2B17 deletion polymorphism. The glucuronidation activity on 19-norandrosterone was significantly higher in UGT2B15 DD than in the other UGT2B15 genotypes (p &lt; 0.05). Moreover, human liver cancer HepG2 cells were exposed to androgens to determine if the transcriptional activity of the genes of interest was affected. Only UGT2B7 mRNA expression was significantly increased (1.8-folds) after incubation with nandrolone decanoate. These results show that the UGT2B7 and UGT2B15 are involved in 19-norandrosterone glucuronidation and that the UGT2B15 polymorphism (D85Y) is the only UGT genetic variation that influences the glucuronidation activity. This could partly explain the inter-individual variation in 19-norandrosterone excretion.</description><subject>19-norandrosterone</subject><subject>anabolic androgenic steroid</subject><subject>Endocrinology</subject><subject>Endokrinologi och diabetes</subject><subject>Klinisk medicin</subject><subject>Medicin och hälsovetenskap</subject><subject>Nandrolone</subject><subject>UGT2B15</subject><subject>UGT2B7</subject><issn>1664-2392</issn><issn>1664-2392</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2013</creationdate><recordtype>article</recordtype><sourceid>DOA</sourceid><recordid>eNp1UstuFDEQtBARiULunNAcOWQWvx8XJBJBstKSXDZny_b0hAkz48WeBfH3eB9ZsgdOLnVXVbfahdA7gmeMafOxhbGJM4oJm2GMlXiFzoiUvKbM0Ncv8Cm6yPmpUDDHxBj9Bp1SprEgVJ2hxXxY9V1wUxfHKrbV7XpwY_Vws6RX6rKiV0RcVm5sNkhV3VgRU9_FVCop5glSHKH6BpPzse_y8BadtK7PcLF_z9Hy65fl9W29uL-ZX39e1IFLIWoduA6UYEMMbzy4BrSUWnLSirag0jXSa859oBJT5zwFIwFCYNobw9g5mu9sm-ie7Cp1g0t_bHSd3RZierQuTV3owQbtwcvGKAJltuOGKq2wwE5KT0D64lXvvPJvWK39kdu-9KMgsIJqIUXhm__yVyk2_0TPQvp87KL9tNMWwgBNgHFKrj-2OOqM3Xf7GH9ZJg3DamPwYW-Q4s815MkOXQ7Q926EuM6WMEWlUZiZQsU7aigflRO0hzEE20187DY-dhMfu41Pkbx_ud5BcNj_LyB8v9w</recordid><startdate>2013</startdate><enddate>2013</enddate><creator>Strahm, Emmanuel</creator><creator>Sjöberg, Ulf</creator><creator>Garle, Mats</creator><creator>Rane, Anders</creator><creator>Ekström, Lena</creator><general>Frontiers Media S.A</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><scope>ADTPV</scope><scope>AOWAS</scope><scope>D8T</scope><scope>ZZAVC</scope><scope>DOA</scope></search><sort><creationdate>2013</creationdate><title>Implication of Human UGT2B7, 2B15, and 2B17 in 19-Norandrosterone Metabolism</title><author>Strahm, Emmanuel ; Sjöberg, Ulf ; Garle, Mats ; Rane, Anders ; Ekström, Lena</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4655-8c48c2109194dbeade8668641f5f866c4896b844bc2602aab2e96eecc38b9933</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2013</creationdate><topic>19-norandrosterone</topic><topic>anabolic androgenic steroid</topic><topic>Endocrinology</topic><topic>Endokrinologi och diabetes</topic><topic>Klinisk medicin</topic><topic>Medicin och hälsovetenskap</topic><topic>Nandrolone</topic><topic>UGT2B15</topic><topic>UGT2B7</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Strahm, Emmanuel</creatorcontrib><creatorcontrib>Sjöberg, Ulf</creatorcontrib><creatorcontrib>Garle, Mats</creatorcontrib><creatorcontrib>Rane, Anders</creatorcontrib><creatorcontrib>Ekström, Lena</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>SwePub</collection><collection>SwePub Articles</collection><collection>SWEPUB Freely available online</collection><collection>SwePub Articles full text</collection><collection>Directory of Open Access Journals</collection><jtitle>Frontiers in endocrinology (Lausanne)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Strahm, Emmanuel</au><au>Sjöberg, Ulf</au><au>Garle, Mats</au><au>Rane, Anders</au><au>Ekström, Lena</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Implication of Human UGT2B7, 2B15, and 2B17 in 19-Norandrosterone Metabolism</atitle><jtitle>Frontiers in endocrinology (Lausanne)</jtitle><addtitle>Front Endocrinol (Lausanne)</addtitle><date>2013</date><risdate>2013</risdate><volume>4</volume><spage>75</spage><epage>75</epage><pages>75-75</pages><issn>1664-2392</issn><eissn>1664-2392</eissn><abstract>Nandrolone (19-nortestosterone) is an anabolic androgenic steroid commonly abused for doping purposes. Nandrolone is mainly metabolized in the liver into 19-norandrosterone prior to glucuronidation and excretion through urine over an extended period of time. Several UGTs (i.e., UGT2B7, UGT2B15, and UGT2B17) are thought to be the major enzymes responsible for conjugation of androgens in human. An in vitro study using recombinant enzymes expressed in insect cells showed that UGT1A4 and UGT2B7 are the two main enzymes responsible of 19-norandrosterone glucuronidation. However, the identity of the enzyme involved in nandrolone metabolism in vivo together with their relative contribution and regulation remain unknown. Inhibition assays using human liver microsomes (HLM) incubated with 19-norandrosterone and selective inhibitors confirmed that UGT2B7 and UGT2B15 are involved in 19-norandrosterone glucuronidation, since the presence of the specific UGT2B7 and UGT2B15 inhibitors gemfibrozil and valproic acid inhibited the 19-norandrosterone glucuronidation by 35 and 45%, respectively. HLM were genotyped for UGT2B15 D85Y, UGT2B7 H268Y, and the UGT2B17 deletion polymorphism. The glucuronidation activity on 19-norandrosterone was significantly higher in UGT2B15 DD than in the other UGT2B15 genotypes (p &lt; 0.05). Moreover, human liver cancer HepG2 cells were exposed to androgens to determine if the transcriptional activity of the genes of interest was affected. Only UGT2B7 mRNA expression was significantly increased (1.8-folds) after incubation with nandrolone decanoate. These results show that the UGT2B7 and UGT2B15 are involved in 19-norandrosterone glucuronidation and that the UGT2B15 polymorphism (D85Y) is the only UGT genetic variation that influences the glucuronidation activity. This could partly explain the inter-individual variation in 19-norandrosterone excretion.</abstract><cop>Switzerland</cop><pub>Frontiers Media S.A</pub><pmid>23805127</pmid><doi>10.3389/fendo.2013.00075</doi><tpages>1</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1664-2392
ispartof Frontiers in endocrinology (Lausanne), 2013, Vol.4, p.75-75
issn 1664-2392
1664-2392
language eng
recordid cdi_doaj_primary_oai_doaj_org_article_c8beb6d971ec46a492787050a66b1e6b
source PubMed Central
subjects 19-norandrosterone
anabolic androgenic steroid
Endocrinology
Endokrinologi och diabetes
Klinisk medicin
Medicin och hälsovetenskap
Nandrolone
UGT2B15
UGT2B7
title Implication of Human UGT2B7, 2B15, and 2B17 in 19-Norandrosterone Metabolism
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-23T13%3A48%3A45IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Implication%20of%20Human%20UGT2B7,%202B15,%20and%202B17%20in%2019-Norandrosterone%20Metabolism&rft.jtitle=Frontiers%20in%20endocrinology%20(Lausanne)&rft.au=Strahm,%20Emmanuel&rft.date=2013&rft.volume=4&rft.spage=75&rft.epage=75&rft.pages=75-75&rft.issn=1664-2392&rft.eissn=1664-2392&rft_id=info:doi/10.3389/fendo.2013.00075&rft_dat=%3Cproquest_doaj_%3E1372697039%3C/proquest_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c4655-8c48c2109194dbeade8668641f5f866c4896b844bc2602aab2e96eecc38b9933%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1372697039&rft_id=info:pmid/23805127&rfr_iscdi=true